GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Waters Corp (MEX:WAT) » Definitions » Cyclically Adjusted PS Ratio

Waters (MEX:WAT) Cyclically Adjusted PS Ratio : 7.68 (As of Jun. 02, 2025)


View and export this data going back to 2019. Start your Free Trial

What is Waters Cyclically Adjusted PS Ratio?

As of today (2025-06-02), Waters's current share price is MXN6942.00. Waters's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 was MXN904.16. Waters's Cyclically Adjusted PS Ratio for today is 7.68.

The historical rank and industry rank for Waters's Cyclically Adjusted PS Ratio or its related term are showing as below:

MEX:WAT' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 5.88   Med: 8.12   Max: 13.58
Current: 7.77

During the past years, Waters's highest Cyclically Adjusted PS Ratio was 13.58. The lowest was 5.88. And the median was 8.12.

MEX:WAT's Cyclically Adjusted PS Ratio is ranked worse than
86.36% of 132 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.06 vs MEX:WAT: 7.77

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Waters's adjusted revenue per share data for the three months ended in Mar. 2025 was MXN226.714. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is MXN904.16 for the trailing ten years ended in Mar. 2025.

Shiller PE for Stocks: The True Measure of Stock Valuation


Waters Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Waters's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Waters Cyclically Adjusted PS Ratio Chart

Waters Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 8.54 11.25 9.12 8.04 8.43

Waters Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.18 6.78 8.29 8.43 8.20

Competitive Comparison of Waters's Cyclically Adjusted PS Ratio

For the Diagnostics & Research subindustry, Waters's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Waters's Cyclically Adjusted PS Ratio Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Waters's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Waters's Cyclically Adjusted PS Ratio falls into.


;
;

Waters Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Waters's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=6942.00/904.16
=7.68

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Waters's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Waters's adjusted Revenue per Share data for the three months ended in Mar. 2025 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=226.714/134.9266*134.9266
=226.714

Current CPI (Mar. 2025) = 134.9266.

Waters Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201506 93.152 100.684 124.833
201509 102.179 100.392 137.329
201512 122.363 99.792 165.444
201603 99.799 100.470 134.025
201606 121.820 101.688 161.639
201609 125.160 101.861 165.789
201612 160.147 101.863 212.130
201703 116.087 102.862 152.274
201706 124.956 103.349 163.135
201709 127.473 104.136 165.164
201712 167.807 104.011 217.685
201803 120.943 105.290 154.986
201806 149.359 106.317 189.551
201809 140.166 106.507 177.567
201812 186.478 105.998 237.371
201903 137.650 107.251 173.171
201906 165.615 108.070 206.773
201909 170.690 108.329 212.598
201912 210.869 108.420 262.422
202003 174.079 108.902 215.680
202006 193.013 108.767 239.434
202009 210.540 109.815 258.685
202012 250.199 109.897 307.184
202103 198.609 111.754 239.790
202106 218.300 114.631 256.949
202109 219.027 115.734 255.348
202112 279.552 117.630 320.659
202203 225.587 121.301 250.927
202206 237.492 125.017 256.317
202209 237.223 125.227 255.598
202212 280.074 125.222 301.780
202303 208.056 127.348 220.438
202306 215.156 128.729 225.515
202309 209.213 129.860 217.376
202312 234.593 129.419 244.576
202403 177.839 131.776 182.091
202406 218.337 132.554 222.245
202409 244.972 133.029 248.467
202412 304.391 133.157 308.436
202503 226.714 134.927 226.714

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Waters  (MEX:WAT) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Waters Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Waters's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Waters Business Description

Traded in Other Exchanges
Address
34 Maple Street, Milford, MA, USA, 01757
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions.